id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC8069884 | core_pubmed_pmc | Modeling Between-Subject Variability in Subcutaneous Absorption of a Fast-Acting Insulin Analogue by a Nonlinear Mixed Effects Approach | Modeling Between-Subject Variability in Subcutaneous Absorption of a Fast-Acting Insulin Analogue by a Nonlinear Mixed Effects Approach Abstract Abstract Despite the great progress made in insulin preparation and titration, many patients with diabetes are still experiencing dangerous fluctuations in their blood glucose... |
PMC8974032 | core_pubmed_pmc | Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications | Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications Abstract ABSTRACT Current study was conducted to design and screen a long-lasting Exendin-4 analog for treating type 2 diabetes via the novel strategy of albumin binding combined with thrombin enzymolysis. First, a seri... |
PMC5980577 | core_pubmed_pmc | Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label | Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label Abstract Osimertinib is a potent, highly selective, irreversible inhibitor of epidermal growth factor receptor (EGFR) and T790M resistance mutation. In vitro metabolism data suggested osimer... |
PMC11201851 | core_pubmed_pmc | Twice weekly dosing with Sebelipase alfa (Kanuma®) rescues severely ill infants with Wolman disease | Twice weekly dosing with Sebelipase alfa (Kanuma®) rescues severely ill infants with Wolman disease Abstract Background Sebelipase alfa (Kanuma®) is approved for patients with Wolman disease (WD) at a dosage of 3–5 mg/kg once weekly. Survival rates in the second of two clinical trials was greater, despite recruiting mo... |
PMC10215324 | core_pubmed_pmc | A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations | A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations Abstract While the relevance of inter-ethnic differences to the pharmacokinetic variabilities of antimicrobials has been reported in studies recruiting healthy subjects, differences in antimicrobial pharmacoki... |
PMC10215740 | core_pubmed_pmc | Concentrations of Co-Administered Meropenem and Vancomycin in Spinal Tissues Relevant for the Treatment of Pyogenic Spondylodiscitis—An Experimental Microdialysis Study | Concentrations of Co-Administered Meropenem and Vancomycin in Spinal Tissues Relevant for the Treatment of Pyogenic Spondylodiscitis—An Experimental Microdialysis Study Abstract Co-administration of meropenem and vancomycin has been suggested as a systemic empirical antibiotic treatment of pyogenic spondylodiscitis. Th... |
PMC9298570 | core_pubmed_pmc | Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice | Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice Abstract The elderly patients with type 2 diabetes suffer more adverse drug events than young adults due to pharmacokinetic and pharmacodynamic changes associated with aging. Reducing the risks of these medication-related problems ... |
PMC5038332 | core_pubmed_pmc | Population Pharmacokinetic Modeling of Tribendimidine Metabolites in Opisthorchis viverrini -Infected Adults | Population Pharmacokinetic Modeling of Tribendimidine Metabolites in Opisthorchis viverrini -Infected Adults Abstract There is a pressing need for alternative treatments against the liver fluke Opisthorchis viverrini . Oral tribendimidine is a promising candidate, but its population pharmacokinetic properties are unkno... |
PMC3050838 | core_pubmed_pmc | Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients | Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients Abstract Background Critical illness, mediated by trauma or sepsis, can lead to physiological changes that alter the pharmacokinetics of antibiotics and may result in s... |
PMC10116112 | core_pubmed_pmc | ERAS Protocol Options for Perioperative Pain Management of Substance Use Disorder in the Ambulatory Surgical Setting | ERAS Protocol Options for Perioperative Pain Management of Substance Use Disorder in the Ambulatory Surgical Setting Abstract Abstract Abstract Even prior to the COVID-19 pandemic, rates of ambulatory surgeries and ambulatory patients presenting with substance use disorder were increasing, and the end of lockdown has f... |
PMC4633976 | core_pubmed_pmc | S -glutathionylation of buccal cell proteins as biomarkers of exposure to hydrogen peroxide | S -glutathionylation of buccal cell proteins as biomarkers of exposure to hydrogen peroxide Abstract Background Exogenous or endogenous hydrogen peroxide (H 2 O 2 ) is a reactive oxygen species (ROS) that can lead to oxidation of cellular nucleophiles, particularly cysteines in proteins. Commercial mouthwashes containi... |
PMC8434012 | core_pubmed_pmc | Effect of Water Extract of Mangosteen Pericarp on Donepezil Pharmacokinetics in Mice | Effect of Water Extract of Mangosteen Pericarp on Donepezil Pharmacokinetics in Mice Abstract Abstract The pharmacokinetic (PK) change in a drug by co-administered herbal products can alter the efficacy and toxicity. In the circumstances that herb–drug combinations have been increasingly attempted to alleviate Alzheime... |
PMC8368277 | core_pubmed_pmc | A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68 Ga-DOTATATE in patients without neuroendocrine tumors | A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68 Ga-DOTATATE in patients without neuroendocrine tumors Abstract Background Physiologically based pharmacokinetic (PBPK) models combine drug-specific information with prior knowledge on the physiology and biology at the organism lev... |
PMC11241507 | core_pubmed_pmc | Inter-Species Pharmacokinetic Modeling and Scaling for Drug Repurposing of Pyronaridine and Artesunate | Inter-Species Pharmacokinetic Modeling and Scaling for Drug Repurposing of Pyronaridine and Artesunate Abstract Abstract Even though several new targets (mostly viral infection) for drug repurposing of pyronaridine and artesunate have recently emerged in vitro and in vivo, inter-species pharmacokinetic (PK) data that c... |
PMC7730577 | core_pubmed_pmc | Synthesis of [ 18 F]F-γ-T-3, a Redox-Silent γ-Tocotrienol (γ-T-3) Vitamin E Analogue for Image-Based In Vivo Studies of Vitamin E Biodistribution and Dynamics | Synthesis of [ 18 F]F-γ-T-3, a Redox-Silent γ-Tocotrienol (γ-T-3) Vitamin E Analogue for Image-Based In Vivo Studies of Vitamin E Biodistribution and Dynamics Abstract Vitamin E, a natural antioxidant, is of interest to scientists, health care pundits and faddists; its nutritional and biomedical attributes may be valid... |
PMC3975086 | core_pubmed_pmc | Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update | Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update Abstract Proton pump inhibitors (PPIs) are used extensively for the treatment of gastric acid-related disorders, often over the long term, which raises the potential for clinically significant drug interactions in patients receiving concomit... |
PMC4029899 | core_pubmed_pmc | Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4 | Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4 Abstract Fluoxetine and its circulating metabolite norfluoxetine present a complex multiple inhibitor system that causes reversible or time-dependent inhibition of CYP2D6, CYP3A... |
PMC9408554 | core_pubmed_pmc | Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations | Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations Abstract Bacterial prostatitis infections are described as infections that are difficult-to-treat, due to prostate anatomic characteristics along with clinical difficulty in terms of di... |
PMC11125186 | core_pubmed_pmc | In Vitro Stability and Pharmacokinetic Study of Pedunculoside and Its Beta-CD Polymer Inclusion Complex | In Vitro Stability and Pharmacokinetic Study of Pedunculoside and Its Beta-CD Polymer Inclusion Complex Abstract Abstract Pedunculoside, a triterpene saponin derived from various Ilex species, holds potential as a treatment for cardiovascular diseases. However, its clinical application is hindered by poor bioavailabili... |
PMC9043134 | core_pubmed_pmc | Effects of Posaconazole on Tacrolimus Population Pharmacokinetics and Initial Dose in Children With Crohn’s Disease Undergoing Hematopoietic Stem Cell Transplantation | Effects of Posaconazole on Tacrolimus Population Pharmacokinetics and Initial Dose in Children With Crohn’s Disease Undergoing Hematopoietic Stem Cell Transplantation Abstract Abstract The present study explored the effects of posaconazole on tacrolimus population pharmacokinetics (PPK) in children with Crohn’s disease... |
PMC12653777 | core_pubmed_pmc | Impact of Complex Genetic and Drug–Drug Interactions on Tamoxifen Metabolism and Efficacy | Impact of Complex Genetic and Drug–Drug Interactions on Tamoxifen Metabolism and Efficacy Abstract Abstract Tamoxifen remains the standard treatment for hormone-sensitive breast cancer. However, significant interindividual variability in treatment response is observed. This variability may be partially explained by dif... |
PMC5336540 | core_pubmed_pmc | Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies | Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies Abstract Abstract Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is rapidly metabolized to... |
PMC4235474 | core_pubmed_pmc | A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban | A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban Abstract Abstract Background Currently, there are no direct comparisons of apixaban and rivaroxaban, two new oral direct factor Xa inhibitors approved for management of thromboembolic disorders. Objective Compare the... |
PMC12882756 | core_pubmed_pmc | Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis | Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis Abstract Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized... |
PMC8818876 | core_pubmed_pmc | Plasma Pharmacokinetics of Cannabidiol Following Oral Administration of Cannabidiol Oil to Dairy Calves | Plasma Pharmacokinetics of Cannabidiol Following Oral Administration of Cannabidiol Oil to Dairy Calves Abstract Cannabidiol (CBD), the non-psychotropic component of cannabis, has drawn increased interest amongst some medical professionals for its potential therapeutic effects. Human and canine work has been done to de... |
PMC9295577 | core_pubmed_pmc | Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment | Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment Abstract ABSTRACT The rate at which parasitemia declines in a host after treatment with an antimalarial drug is a major metric for assessment of antimalarial drug activity in preclinical models and in... |
PMC12647727 | core_pubmed_pmc | Engineering a single-chain immunoglobulin scaffold loaded with a latent-releasable cytotoxic pore-forming peptide | Engineering a single-chain immunoglobulin scaffold loaded with a latent-releasable cytotoxic pore-forming peptide Abstract Abstract Pore-forming peptides (PFPs) hold strong anti-tumor potential but require delivery systems to ensure stability and prevent off-target effects. In this study, we develop a strategy to trans... |
PMC7032191 | core_pubmed_pmc | Bioactive flavonoids in medicinal plants: Structure, activity and biological fate | Bioactive flavonoids in medicinal plants: Structure, activity and biological fate Abstract Flavonoids, a class of polyphenol secondary metabolites, are presented broadly in plants and diets. They are believed to have various bioactive effects including anti-viral, anti-inflammatory, cardioprotective, anti-diabetic, ant... |
PMC7723585 | core_pubmed_pmc | Pharmacogenetic and safety analysis of cinacalcet hydrochloride in healthy Chinese subjects | Pharmacogenetic and safety analysis of cinacalcet hydrochloride in healthy Chinese subjects Abstract Abstract Background Our study aims to explore the effect of genetics on the pharmacodynamics (PD) and pharmacokinetics (PK) of cinacalcet in healthy Chinese subjects; to investigate the effect of dietary factors on cina... |
PMC10366925 | core_pubmed_pmc | Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier | Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier Abstract Drug development for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease has challenging difficulties due to the pharmacokinetic impermeability based on the blood-brai... |
PMC11788964 | core_pubmed_pmc | Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease | Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease Abstract Abstract This review demonstrates the value of central pharmacodynamics (PD), including positron emission tomography (PET) and computerized cogni... |
PMC12110731 | core_pubmed_pmc | Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants | Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants Abstract Abstract Omaveloxolone is approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years. It is mainly metabolized by cytochrome P450 (CYP) 3A4 in ... |
PMC5222895 | core_pubmed_pmc | A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus | A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus Abstract Background Due to population aging, an increasing number of elderly patients with diabetes use insulin. It is therefore important to investiga... |
PMC7389877 | core_pubmed_pmc | Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects | Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects Abstract Abstract Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the western adult population; it is also prevalent worldwide. The B cell lymphoma-2 (BCL-2) family proteins play a key rol... |
PMC3257201 | core_pubmed_pmc | Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients | Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients Abstract Abstract Background Nephropathic cystinosis is an autosomal recessive disorder resulting in an impaired transport of cystine trough the lysosomal membrane causing an accumulation of free cystine in lysosomes. The... |
PMC5812400 | core_pubmed_pmc | Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours | Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours Abstract Abstract Background Sapanisertib (TAK-228) is an investigational, orally available, potent and highly selective mTORC1/2 inhibitor d... |
PMC8731678 | core_pubmed_pmc | Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era | Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era Abstract Abstract The coronavirus disease 2019 (COVID-19) pandemic has prompted significant changes in patient care in rheumatology and gastroenterology, with clinical guidance issue... |
PMC7275616 | core_pubmed_pmc | Sex differences in pharmacokinetics predict adverse drug reactions in women | Sex differences in pharmacokinetics predict adverse drug reactions in women Abstract Background Women experience adverse drug reactions, ADRs, nearly twice as often as men, yet the role of sex as a biological factor in the generation of ADRs is poorly understood. Most drugs currently in use were approved based on clini... |
PMC10875465 | core_pubmed_pmc | Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2 | Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2 Abstract Background APN01 is a soluble recombinant human angiotensin-converting enzyme 2 (rhACE2), a key player in the renin–aldosterone–angiotensin system (RAAS). In clinical stu... |
PMC12566644 | core_pubmed_pmc | Hepatoprotective Effect of Silymarin Herb in Prevention of Liver Dysfunction Using Pig as Animal Model | Hepatoprotective Effect of Silymarin Herb in Prevention of Liver Dysfunction Using Pig as Animal Model Abstract Silymarin, a flavonolignan-rich extract of Silybum marianum , is widely recognized for its hepatoprotective potential. While rodent studies predominate, pigs ( Sus scrofa ) offer a more translationally releva... |
PMC10560686 | core_pubmed_pmc | Drug-microbiota interactions: an emerging priority for precision medicine | Drug-microbiota interactions: an emerging priority for precision medicine Abstract Individual variability in drug response (IVDR) can be a major cause of adverse drug reactions (ADRs) and prolonged therapy, resulting in a substantial health and economic burden. Despite extensive research in pharmacogenomics regarding t... |
PMC10815719 | core_pubmed_pmc | Impact of Sinapic Acid on Bovine Serum Albumin Thermal Stability | Impact of Sinapic Acid on Bovine Serum Albumin Thermal Stability Abstract Abstract The thermal stability of bovine serum albumin (BSA) in Tris buffer, as well as the effect of sinapic acid (SA) on protein conformation were investigated via calorimetric (differential scanning microcalorimetry—μDSC), spectroscopic (dynam... |
PMC6523206 | core_pubmed_pmc | Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients | Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients Abstract Abstract The protein therapeutic and CD95L inhibitor asunercept is currently under clinical investigation for the treatment of glioblastoma ... |
PMC10359452 | core_pubmed_pmc | Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia | Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia Abstract Abstract In the treatment of childhood acute lymphoblastic leukemia (ALL), current protocols combine initial high-dose multiagent chemotherapy with prolonged oral therapy with 6-mercaptopurine (6MP) and l... |
PMC10338470 | core_pubmed_pmc | Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors | Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors Abstract Background GSK3368715, a first-in-class, reversible inhibitor of type I protein methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This Phase 1 study ( NCT03666988 ) evaluated safety, p... |
PMC6161302 | core_pubmed_pmc | Oral Bioavailability of Kinsenoside in Beagle Dogs Measured by LC-MS/MS: Improvement of Ex Vivo Stability of a Lactone-Containing Compound | Oral Bioavailability of Kinsenoside in Beagle Dogs Measured by LC-MS/MS: Improvement of Ex Vivo Stability of a Lactone-Containing Compound Abstract Kinsenoside (KD), an active compound isolated from Anoectochilus roxburghii , has demonstrated multiple pharmacological activities including hepatoprotection, antihyperlipo... |
PMC4875928 | core_pubmed_pmc | Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms | Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms Abstract Abstract Since many drugs are cytochrome P450 (CYP)-3A4 substrates, it has become common practice to assess drug–drug interaction (DDI) potential with... |
PMC6831736 | core_pubmed_pmc | Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A | Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A Abstract Tyramine, formed by the decarboxylation of tyrosine, is a natural constituent of numerous food products. As an indirect sympathomimetic, it can have potentially dangerous hypertensive effects. In vitro data indi... |
PMC5931679 | core_pubmed_pmc | Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial | Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial Abstract Abstract Background Bedaquiline, an antimycobacterial agent approved for drug-resistant tuberculosis, is metabolized by CYP3A4, an hepatic enzyme strongly ind... |
PMC4041992 | core_pubmed_pmc | A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA | A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA Abstract Abstract Protein-based methods of targeted short-interfering RNA (siRNA) delivery have the potential to solve some of the problems faced by nanoparticle-based methods, such as poor pharmacokinetics and biodistribution... |
PMC12729921 | core_pubmed_pmc | Advances and Challenges in Drug Screening for Cancer Therapy: A Comprehensive Review | Advances and Challenges in Drug Screening for Cancer Therapy: A Comprehensive Review Abstract Cancer drug screening is shifting from low-predictive, reductionist assays to human-relevant, data-integrated platforms. This review synthesizes preclinical strategies using a unified lens—Principle, Advantages, Limitations, a... |
PMC3391055 | core_pubmed_pmc | Pharmacokinetics of Piperaquine in Pregnant Women in Sudan with Uncomplicated Plasmodium falciparum Malaria | Pharmacokinetics of Piperaquine in Pregnant Women in Sudan with Uncomplicated Plasmodium falciparum Malaria Abstract Abstract The pharmacokinetic properties of piperaquine were investigated in 12 pregnant and 12 well-matched, non-pregnant women receiving a three-day oral fixed dose combination regimen of dihydroartemis... |
PMC7920706 | core_pubmed_pmc | Study on Quality Standards and Hepatoprotective Effect of Curcuma phaeocaulis Radix | Study on Quality Standards and Hepatoprotective Effect of Curcuma phaeocaulis Radix Abstract Curcuma phaeocaulis Radix (Lüsiyujin) is a mainstream variety of Curcumae Radix cultivated in Sichuan for more than 900 years, but its broader utility is limited by a lack of quality control and pharmacodynamic research. We use... |
PMC11510572 | core_pubmed_pmc | Linezolid Adsorption on Filters during Continuous Renal Replacement Therapy: An In Vitro Study | Linezolid Adsorption on Filters during Continuous Renal Replacement Therapy: An In Vitro Study Abstract Abstract Background: Renal replacement therapy (RRT), widely used in the treatment of renal injury during sepsis, aims to eliminate the toxins and proinflammatory cytokines involved in the pathomechanism underlying s... |
PMC9685987 | core_pubmed_pmc | Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic | Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic Abstract Abstract Pharmacological therapy is the mainstay of treatment for cancer patients. Despite wide interpatient variability in systemic drug concentrations for numerous antineoplastics, dosing based on body size rem... |
PMC3661230 | core_pubmed_pmc | Gabapentin Enacarbil: Pharmacotherapy of Restless Legs Syndrome | Gabapentin Enacarbil: Pharmacotherapy of Restless Legs Syndrome Abstract Restless Legs Syndrome (RLS) is a prevalent sleep-associated movement disorder greatly affecting patients’ quality of life (QoL). Several drugs can be used to control this condition although the first-line dopamine agents often cause adverse effec... |
PMC8069088 | core_pubmed_pmc | Pharmacokinetics and Pharmacodynamics of a Depolymerized Glycosaminoglycan from Holothuria fuscopunctata , a Novel Anticoagulant Candidate, in Rats by Bioanalytical Methods | Pharmacokinetics and Pharmacodynamics of a Depolymerized Glycosaminoglycan from Holothuria fuscopunctata , a Novel Anticoagulant Candidate, in Rats by Bioanalytical Methods Abstract dHG-5 (Mw 5.3 kD) is a depolymerized glycosaminoglycan from sea cucumber Holothuria fuscopunctata . As a selective inhibitor of intrinsic ... |
PMC4579266 | core_pubmed_pmc | Pharmaceutical Management of Trigeminal Neuralgia in the Elderly | Pharmaceutical Management of Trigeminal Neuralgia in the Elderly Abstract Abstract Classical trigeminal neuralgia (CTN) is a severe neuropathic pain in the distribution of one or more branches of the trigeminal nerve, which occurs in recurrent episodes, causing deterioration in quality of life, affecting everyday habit... |
PMC11702898 | core_pubmed_pmc | Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients | Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients Abstract Abstract Background: For extended-release drug formulations, effective half-life (t 1/2eff ) is a relevant pharmacokinetic parameter to inform dosing strategies a... |
PMC12198074 | core_pubmed_pmc | Enhancing the therapeutic potential of FDA-approved ifosfamide and 5-fluorouracil through rational chemical modifications for endometrial cancer treatment | Enhancing the therapeutic potential of FDA-approved ifosfamide and 5-fluorouracil through rational chemical modifications for endometrial cancer treatment Abstract Endometrial or uterine cancers predominantly occur in postmenopausal women, thereby establishing a strong correlation with advanced age. The chemotherapeuti... |
PMC8317223 | core_pubmed_pmc | Properties, Pharmacology, and Pharmacokinetics of Active Indole and Oxindole Alkaloids in Uncaria Hook | Properties, Pharmacology, and Pharmacokinetics of Active Indole and Oxindole Alkaloids in Uncaria Hook Abstract Uncaria Hook (UH) is a dry stem with hook of Ucaria plant and is contained in Traditional Japanese and Chinese medicine such as yokukansan, yokukansankachimpihange, chotosan, Gouteng-Baitouweng, and Tianma-Go... |
PMC12655608 | core_pubmed_pmc | Influence of CYP2D6, CYP3A, and ABCG2 Genetic Polymorphisms on Ibrutinib Disposition in Chinese Healthy Subjects | Influence of CYP2D6, CYP3A, and ABCG2 Genetic Polymorphisms on Ibrutinib Disposition in Chinese Healthy Subjects Abstract Abstract Objectives : This study aimed to elucidate the determinants of interindividual variability in the pharmacokinetics of ibrutinib among healthy Chinese subjects, focusing on the influence of ... |
PMC3750111 | core_pubmed_pmc | Solvent effects on the structure-property relationship of anticonvulsant hydantoin derivatives: A solvatochromic analysis | Solvent effects on the structure-property relationship of anticonvulsant hydantoin derivatives: A solvatochromic analysis Abstract Considering the pharmaceutical importance of hydantoins, a set of 25 derivatives of phenytoin, nirvanol and 5-methyl-5-phenylhydantoin, the lipophilicities of which were gradually increased... |
PMC11666954 | core_pubmed_pmc | Exploring the therapeutic potential of triterpenoid saponins from Gymnema sylvestre : Mechanistic insights into hepatoprotection, immunomodulation, anticancer activities, molecular docking, and pharmacokinetics | Exploring the therapeutic potential of triterpenoid saponins from Gymnema sylvestre : Mechanistic insights into hepatoprotection, immunomodulation, anticancer activities, molecular docking, and pharmacokinetics Abstract The study comprehensively investigated the therapeutic potential of Gymnema sylvestre triterpenoid s... |
PMC5754392 | core_pubmed_pmc | Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease | Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease Abstract Abstract Purpose Data on panitumumab dosing in cancer patients with renal insufficiency are lacking. Here, we report a 63-year-old metastatic colorectal cancer patient with chronic kidney injury with a glomerular filtration rat... |
PMC11920041 | core_pubmed_pmc | Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease | Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease Abstract Multiple factors affect the absorption of orally administered levodopa, the gold standard for the treatment of Parkinson’s disease (PD). Enterococcus faecalis ( E. faecalis ) expres... |
PMC4729772 | core_pubmed_pmc | Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding | Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding Abstract Abstract The efficacy of therapeutic drugs is highly dependent on their optimal in vivo pharmacokinetics. Albumin conjugation is considered to be one of the most effective means of protracting ... |
PMC12662848 | core_pubmed_pmc | Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer | Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer Abstract Purpose Castration and enzalutamide induce BCL-2 to drive therapy resistance in prostate cancer (PCa). We conducted a phase Ib trial to test that metastatic castration-resistant PCa (mCRPC) can be ef... |
PMC11714858 | core_pubmed_pmc | A case report of exacerbation of extrapyramidal symptoms following the switch from risperidone to paliperidone during valproate therapy | A case report of exacerbation of extrapyramidal symptoms following the switch from risperidone to paliperidone during valproate therapy Abstract Background Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an ext... |
PMC7662179 | core_pubmed_pmc | A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects | A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects Abstract Abstract Background Clostridioides difficile infection is the most common cau... |
PMC10674351 | core_pubmed_pmc | Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases | Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases Abstract Abstract Background: Limited pharmacotherapy and the failure of conventional treatments in complex pathologies in children lead to increased off-label use of ritux... |
PMC9340310 | core_pubmed_pmc | The role of efflux transporters and metabolizing enzymes in brain and peripheral organs to explain drug‐resistant epilepsy | The role of efflux transporters and metabolizing enzymes in brain and peripheral organs to explain drug‐resistant epilepsy Abstract Abstract Drug‐resistant epilepsy has been explained by different mechanisms. The most accepted one involves overexpression of multidrug transporters proteins at the blood brain barrier and... |
PMC4700710 | core_pubmed_pmc | Does Ethnic Variability Exist in the Systemic Exposures of OATP1A2 Substrates–Fexofenadine in Taiwanese? | Does Ethnic Variability Exist in the Systemic Exposures of OATP1A2 Substrates–Fexofenadine in Taiwanese? Abstract The aim of this study was to investigate differences in organic anion transporting polypeptide 1A2 activity among the Taiwanese population via an analysis of 3 pharmacokinetic studies completed in a total o... |
PMC3235423 | core_pubmed_pmc | New Formulations of Local Anaesthetics—Part I | New Formulations of Local Anaesthetics—Part I Abstract Abstract Part 1 comments on the types of local anaesthetics (LAs); it provides a better understanding of the mechanisms of action of LAs, and their pharmacokinetics and toxicity. It reviews the newer LAs such as levobupivacaine, ropivacaine, and articaine, and exam... |
PMC4215585 | core_pubmed_pmc | A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer | A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer Abstract Transforming growth factor β (TGF-β) plays an important role in cancer. Monoclonal antibodies (mAb) designed to specifically block the TGF-β ligands, are expecte... |
PMC5477094 | core_pubmed_pmc | Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis | Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis Abstract Abstract Background ONO-5334 is a cathepsin K inhibitor that induced bone mineral density (BMD) gain in a phase II study in postmenopausal osteoporosis patients. Ev... |
PMC7775160 | core_pubmed_pmc | Area under the Curve-Based Dosing of Vancomycin in Critically Ill Patients Using 6-Hour Urine Creatinine Clearance Measurement | Area under the Curve-Based Dosing of Vancomycin in Critically Ill Patients Using 6-Hour Urine Creatinine Clearance Measurement Abstract Abstract Background The area under the curve- (AUC-) guided vancomycin dosing is the best strategy for individualized therapy in critical illnesses. Since AUC can be calculated directl... |
PMC12288328 | core_pubmed_pmc | Assessing blood-brain barrier (BBB) integrity in an Alzheimer’s disease mouse model: is the BBB globally or locally disrupted? | Assessing blood-brain barrier (BBB) integrity in an Alzheimer’s disease mouse model: is the BBB globally or locally disrupted? Abstract Alzheimer’s disease (AD), marked by amyloid-beta (Aβ) plaques and tau tangles, involves cerebral amyloid angiopathy (CAA), which may compromise blood-brain barrier (BBB) integrity. How... |
PMC12888871 | core_pubmed_pmc | Population pharmacokinetics of caspofungin in critically ill Chinese children: a prospective observational study | Population pharmacokinetics of caspofungin in critically ill Chinese children: a prospective observational study Abstract ABSTRACT While caspofungin is increasingly used to treat invasive fungal infections in pediatric intensive care unit (PICU) patients, its pharmacokinetic profile in this population remains poorly un... |
PMC6717388 | core_pubmed_pmc | The “rights” of precision drug development for Alzheimer’s disease | The “rights” of precision drug development for Alzheimer’s disease Abstract Abstract There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug devel... |
PMC12297905 | core_pubmed_pmc | Mechanistic Insights into Cytokine Antagonist-Drug Interactions: A Physiologically Based Pharmacokinetic Modelling Approach with Tocilizumab as a Case Study | Mechanistic Insights into Cytokine Antagonist-Drug Interactions: A Physiologically Based Pharmacokinetic Modelling Approach with Tocilizumab as a Case Study Abstract Abstract Background: Understanding interactions between cytokine antagonists and drugs is essential for effective medication management in inflammatory co... |
PMC9519353 | core_pubmed_pmc | Effect of Ketorolac on Pharmacokinetics and Pharmacodynamics of 5-Fluorouracil: In Vivo and In Vitro Study | Effect of Ketorolac on Pharmacokinetics and Pharmacodynamics of 5-Fluorouracil: In Vivo and In Vitro Study Abstract Background This study aimed to evaluate the impact of ketorolac on the pharmacokinetics of 5-FU and its effect on the efficacy of 5-fluorouracil (5-FU) on the HT-29 cell line. Methods Cell culture: the HT... |
PMC3127140 | core_pubmed_pmc | In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG) | In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG) Abstract HM-3, designed by our laboratory, is a polypeptide composed of 18 amino acids. Pharmacodynamic studies in vivo and in vitro indicated that HM-3 could inhibit endothelial cell migration and angiogenesis, thereby inh... |
PMC4940435 | core_pubmed_pmc | Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease | Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease Abstract Purpose Immune globulins for IgG supplementation have been produced for over 35 years with es... |
PMC5676495 | core_pubmed_pmc | Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature | Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature Abstract Background: Whether arrhythmia risks will increase if drugs with electrocardiographic (ECG) QT-prolonging properties are combined is generally supposed but not well studi... |
PMC12827303 | core_pubmed_pmc | The role of oral amoxicillin/clavulanic acid in the treatment of osteomyelitis: a systematic review | The role of oral amoxicillin/clavulanic acid in the treatment of osteomyelitis: a systematic review Abstract Purpose Osteomyelitis continues to pose significant challenges in clinical management, with no universally accepted treatment guidelines at either national or international level as of 2025. Amoxicillin/clavulan... |
PMC9963741 | core_pubmed_pmc | In Silico Studies to Support Vaccine Development | In Silico Studies to Support Vaccine Development Abstract Abstract The progress that has been made in computer science positioned in silico studies as an important and well-recognized methodology in the drug discovery and development process. It has numerous advantages in terms of costs and also plays a huge impact on ... |
PMC12673270 | core_pubmed_pmc | Pharmacokinetics of mycophenolic acid in plasma and peripheral blood mononuclear cells and its relationship with activity of inosine monophosphate dehydrogenase in Chinese adult kidney allograft recipients | Pharmacokinetics of mycophenolic acid in plasma and peripheral blood mononuclear cells and its relationship with activity of inosine monophosphate dehydrogenase in Chinese adult kidney allograft recipients Abstract Abstract Aims We aimed to study the pharmacokinetics (PK) of mycophenolic acid (MPA) in plasma and periph... |
PMC11986180 | core_pubmed_pmc | ZIF-8 Selective Dispersive Solid-Phase Extraction-LC-MS/MS Method for the Determination of Aconitine alkaloids in Rat Plasma: Application in Pharmacokinetic Studies | ZIF-8 Selective Dispersive Solid-Phase Extraction-LC-MS/MS Method for the Determination of Aconitine alkaloids in Rat Plasma: Application in Pharmacokinetic Studies Abstract Objective: Aconitine alkaloids, as the principal bioactive constituents of Fuzi, pose a significant challenge to its clinical application due to t... |
PMC5947143 | core_pubmed_pmc | Single‐Dose Pharmacokinetic Study of Diphenhydramine HCl in Children and Adolescents | Single‐Dose Pharmacokinetic Study of Diphenhydramine HCl in Children and Adolescents Abstract Abstract Diphenhydramine pharmacokinetics were characterized following a single oral dose in children aged 2 to 17 years using a weight‐ and age‐based dosing schedule with more tiers than the current age‐based dosing schedule ... |
PMC10791706 | core_pubmed_pmc | Exploring the influence of the microbiome on the pharmacology of anti-asthmatic drugs | Exploring the influence of the microbiome on the pharmacology of anti-asthmatic drugs Abstract The microbiome is increasingly implicated in playing a role in physiology and pharmacology; in this review, we investigate the literature on the possibility of bacterial influence on the pharmacology of anti-asthmatic drugs, ... |
PMC12894493 | core_pubmed_pmc | Development of a High‐Throughput LC–MS/MS Method for Simultaneous Quantification of Four Therapeutic Monoclonal Antibodies in Human Serum: Application in Clinical Therapeutic Drug Monitoring | Development of a High‐Throughput LC–MS/MS Method for Simultaneous Quantification of Four Therapeutic Monoclonal Antibodies in Human Serum: Application in Clinical Therapeutic Drug Monitoring Abstract ABSTRACT Monoclonal antibody (mAb) therapies have revolutionized cancer treatment, significantly improving patient outco... |
PMC11919270 | core_pubmed_pmc | Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain | Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain Abstract Abstract Intranasal diamorphine (IND), approved for managing breakthrough pain in the UK, has been identified as an acceptable alternative offering effective, expedient, and less traumatic analgesia for ch... |
PMC10427837 | core_pubmed_pmc | Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies | Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies Abstract Abstract Therapeutic monoclonal antibodies (TmAb) have emerged as effective treatments for a number of cancers and autoimmune diseases. However, large interpatient disparities in the pharmacokinetics of TmAb treatment requires close the... |
PMC8507113 | core_pubmed_pmc | Application of modified Michaelis – Menten equations for determination of enzyme inducing and inhibiting drugs | Application of modified Michaelis – Menten equations for determination of enzyme inducing and inhibiting drugs Abstract Background Pharmacokinetics (PK) is the process of absorption, distribution, metabolism and elimination (ADME) of drugs. Some drugs undergo zero-order kinetics (ethyl alcohol), first order kinetics (p... |
PMC4358333 | core_pubmed_pmc | “Robo-Tripping”: Dextromethorphan Abuse and its Anesthetic Implications | “Robo-Tripping”: Dextromethorphan Abuse and its Anesthetic Implications Abstract Abstract Introduction: We describe a patient scheduled for elective surgery who regularly consumed approximately 12 to 15 times the maximum recommended daily dose of dextromethorphan. We describe the clinical pharmacology of dextromethorph... |
PMC5443018 | core_pubmed_pmc | Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study | Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study Abstract Background: The antibiotic meropenem is commonly administered in patients with severe sepsis and septic shock. We co... |
PMC6856258 | core_pubmed_pmc | Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures | Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures Abstract Abstract Background Patients with thrombocytopenia associated with chronic liver diseas... |
PMC7306898 | core_pubmed_pmc | Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia | Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia Abstract Background: Hydromethylthionine is a potent inhibitor of pathological aggregation of tau and TDP-43 proteins. Objective: To compare hydrom... |
PMC9404625 | core_pubmed_pmc | Development and evaluation of uncertainty quantifying machine learning models to predict piperacillin plasma concentrations in critically ill patients | Development and evaluation of uncertainty quantifying machine learning models to predict piperacillin plasma concentrations in critically ill patients Abstract Background Beta-lactam antimicrobial concentrations are frequently suboptimal in critically ill patients. Population pharmacokinetic (PopPK) modeling is the gol... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.